Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities research analysts at Wells Fargo ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Axsome Therapeutics in a note issued ...

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

It's been a strong day for Axsome Therapeutics. Its shares are now trading at $127.02, marking a 20.1% change since the ...

Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.